Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer

To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer. Both PDOX and DOX could significantly inhibit tumor growth compared with Control ( < 0.05) in both subcutaneous and orthotopic models. Animal survival was much better in PDOX group than DOX group. In peripheral blood test, PDOX group had significantly higher levels of platelets than the Control ( < 0.05), and lymphocyte lower than Control ( < 0.05). There were no significant differences on liver, kidney and cardiac function parameters among three groups ( > 0.05). Immunohistochemistry showed that treatment groups had much higher Tunel than Control ( < 0.05), and PDOX had significantly lower Ki-67 than doxorubicin and Control group ( < 0.01). Western blotting showed that PDOX caused much higher expressions of P53, P21, Aparf-1, pro- and cleaved-caspase 3, compared with DOX. Compared with DOX, PDOX has increased effects but much decreased toxicity in treating animal model of gastric cancer. Animals in subcutaneous model were randomized into Control, doxorubicin, PDOX-L, PDOX-M, and PDOX-H groups. Animals in surgical orthotopic implantation model were randomized into Control, doxorubicin and, peptide-doxorubicin groups. The animals were treated, monitored and examined following a set protocol.